This protocol outlines the essential steps of mass spectrometry-based analysis of protein samples that can be used to identify post-translational arginylation. We describe special considerations for sample preparation and digestion, mass spectrometry analysis using high-precision instruments, database searching for the addition of N-terminal arginine, and multiple steps of automated and manual data validation. Data validation is especially important and involves automated data filtering, manual elimination of mass ambiguities, isotopic peak checking and analysis of the ion fragmentation patterns of the putative arginylated peptides. This protocol is an unambiguous method for the identification of post-translationally arginylated proteins, and it can be used to identify new arginylated proteins. This method provides a definitive answer on the identity of arginylated proteins and peptides in simple and complex protein preparations. It is recommended for studies of arginylation and can be applied to other poorly understood post-translational modifications.
INTRODUCTION
Identification of new post-translational modifications has been a challenge in the development of mass spectrometry-based methods for the detection of modified sites on proteins and peptides. Although some of these modifications (e.g., phosphorylation) affect only specific amino-acid residues with relatively low frequency of occurrence in an average protein, other modifications (e.g., acetylation) affect less-defined sites, such as free N termini of any amino-acid chain. Approximately 80% of eukaryotic proteins are N-terminally acetylated 1 and multiple other modifications occur on proteins in vivo. Arginylation-post-translational addition of arginine onto the N-terminal amino group of proteins and peptides 2,3 -has been recently characterized. This modification had been recently found to be critical in many physiological processes in eukaryotes, including cardiovascular development, angiogenesis, cell motility and general metabolic events, and has been proposed as a new regulatory mechanism of protein functions in vivo 2, [4] [5] [6] .
To understand fully the role of post-translational arginylation, sound analytical approaches are needed to ensure the identification of true post-translational modification from potential artifacts. At present, mass spectrometry is to our knowledge the only method for unambiguous identification of post-translationally arginylated sites on proteins. Such identification is complicated by the relative nonspecificity of the modified sites, the presence of co-translationally incorporated arginines that are often difficult to distinguish from those incorporated post-translationally and a variety of mass ambiguities that arise by other protein modifications. The Nterminal amino group of proteins and peptides in particular is very reactive and various chemical groups can be attached to the N terminus in vivo and during sample preparation. In addition to naturally occurring acetylation, proteins and peptides during sample preparation can undergo modifications by carbamylation (which often occurs in samples prepared in the presence of urea), nonspecific N-terminal alkylation (resulting from treatment with excessive amounts of iodoacetamide or other alkylation reagents) or glycylation (which can occur in samples treated with high concentrations of glycine, frequently used during immunoaffinity purifications and present in SDS-PAGE buffers). These and other modifications produce mass ambiguities that can mimic the addition of arginine onto the N terminus of peptides and can confuse the results of mass spectrometry analysis 7 .
The mass spectrometry-based protocol presented here has been developed during our recent work on global analysis of protein arginylation and identification of proteins arginylated in vivo 2, 5, 6 . This protocol involves restrictive conditions for sample preparation, high-precision mass spectrometry instruments and specialized search strategies, followed by automated and manual validation designed to eliminate mass ambiguities and preserve the maximum amount of true arginylated peptides (see the flow chart in Fig. 1 for the protocol outline). Although this procedure is, to our knowledge, the only presently available method for unambiguous identification of arginylated sites on proteins and peptides, it also has certain limitations by being highly labor intensive and costly, requiring state-of-the-art mass spectrometry set-up, and multiple steps of automated and manual validation. Increased understanding of arginylation as a post-translational modification would lead to new possibilities in perfecting and simplifying arginylation detection methods. Improvement of the mass spectrometry-based detection of arginylation and complementing it with other methods of arginylation detection are among our immediate and longer term research goals.
The method described here can be applied, in principle, to the analysis of any N-terminal peptide modification, with the understanding of the specifics such as mass ambiguities and ionization patterns in each particular case.
Experimental design Sample preparation. In general, any protein solution can be used for the analysis described here. Normally, we prepare proteins from cell lysates obtained in the presence of detergent, by sonication or by grinding of frozen tissues in liquid nitrogen, but we have found little correlation between the specific lysis conditions used and the quality of the protein samples. The specific samples used in each experiment depend on the project goals and the available protein source and enrichment methods. Several considerations, however, should be kept in mind during sample preparation.
First, the probability of detecting arginylated peptides increases greatly with higher sequence coverage during mass spectrometry analysis. To achieve high sequence coverage, it is recommended that samples with high protein abundance and low protein complexity be used whenever possible. Purified proteins should work best. However, we found that identification of arginylated peptides in samples containing hundreds of different proteins can also work well.
Second, protein purification and enrichment methods can affect the abundance of arginylated peptides. At present, little is known about the percentage of each protein that is arginylated in vivo, and the specific conditions required for functional arginylation during normal metabolism and pathological processes in cells and tissues. It is also not known which conditions should be used to preserve or enrich the arginylated form of each protein during sample preparation. In our previous studies, we performed immunoaffinity chromatography, using covalently immobilized antibodies to Nterminally arginylated peptides and non-glycine elution conditions, to obtain samples enriched in arginylated proteins 2 , but it is likely that the use of other enrichment methods could, in principle, be just as successful.
Third, several types of conditions should be avoided during sample preparation. First, the presence of urea at any stage of sample preparation (e.g., during protein solubilization or 2D gel analysis) results in nonspecific carbamylation. We found that carbamylation of N-terminal leucine and isoleucine results in a mass shift that makes these two residues virtually indistinguishable from arginine (carbamylation of leucine or isoleucine, 156.0899; arginine, 156.1011). Therefore, urea should be avoided at all steps of sample preparation and analysis, and if urea has been used, arginylated peptides with preceding leucine or isoleucine in the -1 position should be discarded (see TROUBLESHOOTING for the mass ambiguities that cannot be distinguished from arginylation). Second, the use of high concentrations of glycine, common during immunoaffinity purifications or SDS-polyacrylamide gel electrophoresis (PAGE), could theoretically result in nonspecific addition of glycine onto the free amino groups of the protein's N terminus. We found that a combination of N-terminal valine and glycine nearly equals the mass of arginine (Val+Gly, 156.0899), making it difficult to distinguish from N-terminal arginylation. Therefore, glycine should be avoided during the entire procedure. However, as glycine is also present in vivo and certain proteins contain naturally occurring Val-Gly combination at the N terminus or adjacent to a proteolytic digestion site, all peptides containing N-terminal Valor Gly-Val/Val-Gly sequence that also appear in the searches as arginylated on the residue immediately following this sequence should be omitted during target validation. Glycine ambiguity could also result from nonspecific alkylation (glycine, 57.0215; alkyl group, 57.0215) that occurs in the presence of high concentrations of reducing agents used for the modification of cysteine residues.
Additional consideration for sample preparation concerns the fact that addition of arginine is expected to change the protein's surface charge and isoelectric point. During some preparation methods, such as ion exchange chromatography, this may result in omission of the arginylated protein fraction from the preparation because of its reduced binding, for example, to the anion exchange column or even a specific affinity reagent. Another reason for lower abundance or absence of arginylated protein in a preparation could be due to changes in its specific properties (such as polymerization in the case of actin). Certain preparation methods (e.g., cycles of polymerization and depolymerization routinely used during actin purification) could result in alteration or absence of the arginylated protein fraction from the resulting preparation.
For all these reasons, we recommend that mass spectrometry identification of arginylated sites on proteins should be performed on samples in solution, not subjected to treatment with urea and glycine and not fractionated by 1D or 2D electrophoresis or anion exchange chromatography. We also recommend caution with the use of proteins purified based on their specific in vivo properties, as such purification could unpredictably affect the fraction of arginylated protein in the preparation. On the basis of our experience, immunoaffinity isolation using affinity resins with covalently coupled antibodies (such as CNBr-sepharose or Aminolink agarose) and non-glycine high salt elution conditions (e.g., 3.5 M MgCl 2 ) work best.
Finally, it has been shown that in some cases proteins can be degraded upon addition of N-terminal arginine 8 . Although in such cases arginylation may be a major and critically important step in the regulation of the biological activity of such proteins in vivo, mass spectrometry-based identification of arginylated sites on these proteins would require preparation of these proteins in the presence of inhibitors of proteasome-dependent or -independent degradation.
Although proteins in solution at sufficiently high concentration in buffers that favor protease digestion can in principle be used, we recommend trichloroacetic acid (TCA) precipitation of the protein sample before using it in the subsequent steps because this method enables obtaining protein solution at a desired concentration in an appropriate buffer in one step.
It should be noted that many of the arginylated peptides have low abundance in vivo, and that in an average sample, without using special methods such as immunoaffinity chromatography to enrich for arginylated proteins, arginylated peptides may not be detected in each particular run, even if present in low quantities. Therefore, performing multiple runs with varied protein purification conditions should always be considered in this analysis.
Protein digestion. Generally, the use of multiple proteases (e.g., a combination of trypsin, subtilisin and elastase) increases sequence coverage during mass spectrometry analysis. However, some of these proteases may destroy arginylated peptides by cutting immediately after the arginylated residue or producing peptides too short for reliable identification of arginylation. This is especially true for proteases with low specificity for proteolytic sites. We tried using multiple proteases for digestion and found that trypsin is the optimal enzyme (highly efficient and enabling the maximum sequence coverage during identification for the majority of proteins), despite its ability to cleave C-terminally of arginine in the amino-acid chain. Our preliminary runs showed that the majority of arginylated peptides are still preserved during trypsin digestion, suggesting that trypsin possesses minimal or no exopeptidase activity and does not normally remove the N-terminal arginine from proteins and peptides. Endopeptidase LysC could also be used for the digestion of specific proteins, but it is not efficient enough for large-scale analysis because it is more difficult to handle and cuts too selectively, often producing peptides too large for identification. However, Endo LysC should be used when possible for low-complexity protein solutions and for confirmation of arginylated sites.
Mass spectrometry. As elimination of mass ambiguities often requires detection of the precursor mass-to-charge ratio (m/z) with high accuracy, high-resolution mass spectrometers should be used whenever possible for the analysis of arginylated peptides.
Ideally, a high-resolution instrument, such as an Orbitrap, should be used for tandem mass spectrometry (MS/MS) analysis. However, sometimes it is necessary to use an LTQ instrument. The LTQ has a faster scan rate and is more sensitive than an Orbitrap, which can be advantageous because many of the arginylated peptides are found in low abundance in in vivo samples. Peptides identified with a lower mass accuracy instrument should always be manually validated (see below) and certain mass ambiguities (such as, acetylation of aspartate, which results in a mass shift within 0.6 Da of the mass of arginine) cannot be easily resolved. Lower resolution mass spectrometry (MS1) analysis should be avoided if MS/MS analysis is performed with a low-resolution instrument, as the results of such runs cannot unambiguously differentiate among the possible combinations that match arginine. Data obtained with such instruments can still be correct, but the falsepositive rate is usually high and validation by independent methods would be needed to confirm arginylation of each peptide.
Database search. In principle, any commercially available and/or user-developed programs for identifying the addition of a fixed mass on a peptide's N terminus could be used, such as SEQUEST 9 , Mascot 10 , X!Tandem 11 or OMSSA 12 , but many factors should be accounted for in the development and use of such programs and the validation steps described below should always be performed on the list of initial positives to identify the true arginylation targets. On the basis of our experience, ProLuCID 13 , which we used in our analyses, has better sensitivity and specificity for both modified and non-modified peptide identification compared with SEQUEST, Mascot, X!Tandem and OMSSA. Thus, we recommend ProLuCID over other algorithms.
During our analysis, we used ProLuCID to search for the addition of the specific mass of arginine (156.1011) in the 'differential modification' mode (i.e., assuming that each N-terminal site may or may not be modified by the addition of arginine), with no enzymatic cleavage conditions imposed on the database search.
ProLuCID searches yield the list of all peptides in the samples, with and without modifications. Usually the vast majority of the identified peptides are unmodified peptides. The unmodified peptides similar to those found with modifications could be helpful for manual data filtering to eliminate such ambiguities as Val+Gly or arginine present in the native protein's sequence at or adjacent to the N terminus of the peptide ( Table 1) .
Data filtering. For automated data filtering, we used two filters: DTASelect2.0 followed by delta mass filtering.
For DTASelect2.0 filtering, we use false-positive rate parameter (fp) defined as the ratio of the number of reverse (i.e., false) hits to the number of forward (i.e., true) hits that passed the DTASelect filtering. We filter with the false-positive rate setting of 0.1% (fp 0.001). To ensure that the false-positive rate is constant in the searches for modified and unmodified peptides, DTASelect2.0 applies separate filtering to modified and unmodified peptides, considering the possibilities of tryptic, half tryptic and non-tryptic peptides (--modstat and --trypstat options of DTASelect2.0). One peptide serves as a requirement for the identification of a protein (-p 1 DTASelect2.0 option) as we are looking for a specific modification feature of the protein rather than protein identification in the sample. Note that the high-accuracy precursor mass information is not used in this step.
The deltaMassFilter program can effectively remove most simple ambiguities that result in a significant mass shift. For this filtering, the P value for each peptide precursor mass is calculated as the delta mass (defined as the difference between the measured mass and the theoretical mass) for each modified peptide against the distribution of the delta masses of all the non-modified peptides (Fig. 2) . For each modified peptide, the delta mass P value defines the chance that the observed mass corresponds to this particular peptide and not a highly similar one created by a similar mass shift as a result of another modification. A true hit (i.e., truly arginylated peptide) is assumed to have delta mass distribution similar to the distribution of the unmodified peptides, as evidenced by sufficiently high P value. P value setting above Àp 0.0001 are recommended (see below).
Manual validation.
The modified peptides that passed the DTASelect 2.0 and delta mass filter validation should then be analyzed manually (based on the mass shift in the UniMod database 14 , http://www.unimod.org/) to exclude more complicated ambiguities ( Table 1) . After this step, isotopic peak checking and manual analysis of the b ion peaks in the mass spectrum should be performed.
The presence of the early b ions (especially b 1 -b 3 ) of the correct masses in the ionization spectrum is a strong indication that this peptide is truly arginylated. The mass ambiguity exceptions to this rule are listed in Table 1 , and these cannot be resolved by For biologically important peptides or difficult-to-resolve mass ambiguities we recommend, when possible, comparing the identified mass spectra to the mass spectra of synthetic peptides with identical sequence. Such a comparison can serve as the final proof that a peptide is truly arginylated. For example, in our previous study, we compared standard peptides corresponding to the arginylated and acetylated N-terminal beta actin peptides to resolve the ambiguity between acetylated aspartate (Ac-Asp: 157.03751) and arginine (156.1011), and used differences in ion fragment masses as well as the abundance of the lower mass b ions to verify the arginylated peptide in the in vivo sample 5 . REAGENT SETUP 100% TCA solution Prepare by adding water to the TCA jar so that the final volume of the solution equals the weight of TCA in the jar, e.g. 250 ml for 250 g package of TCA. m CRITICAL Prepare immediately after arrival of reagent and store at 4 1C. Cold acetone solution Store B50 ml of aliquot at À20 1C. Protein reduction solution 1 M TCEP in water (store at À20 1C). Protein alkylation solution 500 mM iodoacetamide in water (freshly made, store in the dark).
MATERIALS
Protein digestion solution 1 1 mg ml À1 trypsin solution in 50 mM ammonium bicarbonate and 5 mM CaCl 2 (store in aliquots at À20 1C; each aliquot after thawing can be used once). Protein digestion solution 2 1 mg ml À1 endopeptidase LysC solution in 50 mM ammonium bicarbonate and 5 mM CaCl 2 (store in aliquots at À20 1C; each aliquot after thawing can be used once). Peptide extraction buffer 5% formic acid (can be stored at room temperature (25 1C) for 1-4 months). Buffers for liquid chromatography MS/MS Buffer A 5% acetonitrile/0.1% formic acid in water (can be stored at room temperature for 1-4 months). Buffer B 80% acetonitrile/0.1% formic acid in water. Buffer C 500 mM ammonium acetate/5% acetonitrile/0.1% formic acid in water (can be stored at room temperature for 1-4 months). 4| For alkylation, add protein alkylation solution to the final concentration of 10 mM, incubate 20 min at room temperature in the dark. m CRITICAL STEP Iodoacetamide is highly unstable and light sensitive. Solution needs to be made fresh and protein alkylation needs to be performed in the dark.
Protein digestion TIMING 1 h to overnight
5| Digest protein solution with trypsin and/or endopeptidase LysC, added to the protein sample at 1:100 weight ratio (i.e., 1 mg of trypsin per 100 mg of protein in the sample). Longer digestion times, up to overnight, and higher enzyme ratios (1:20 for LysC and 1:50 for trypsin) can be used with higher complexity samples.
Mass spectrometry TIMING 1-24 h, depending on the complexity of the sample 6| Stop the digestion reaction by adding 5% formic acid to the protein digestion solution. Collect the soluble fraction containing the extracted peptides. 
BOX 2 | RECOMMENDED GRADIENT CONDITIONS FOR THE MASS SPECTROMETRY ANALYSIS OF COMPLEX SAMPLES
Load complex samples onto strong cation exchange/RP MudPIT column and elute as a 12-step gradient. For each of the gradient steps 1-11, we recommend the following conditions, using buffers A, B and C (described in the REAGENT SETUP): In each salt step, a discrete fraction of the absorbed peptides is displaced from the strong cation exchange column onto the reverse phase resin of the analytical column, and an acetonitrile gradient further elutes and separates these peptides into the mass spectrometer.
and obtain the initial list of putative arginylated peptides. m CRITICAL STEP Depending on the sample preparation conditions, add static modifications to the search, e.g. for cysteine in case of treatment with a reducing reagent (+57.02146). ? TROUBLESHOOTING Automated data filtering TIMING Varies depending on the complexity of the sample and protein database size; usually it takes a few minutes to a couple of hours for DTASelect and less than 1 min for deltaMassFilter 11| Use DTASelect 2.0 algorithm 16, 17 for automated data filtering of the results of the ProLuCID search to eliminate the initial set of the false positives.
12| Use deltaMassFilter on the data from Step 11 for high mass accuracy filtering. Use the P value setting Àp 0.0001 or higher (lower P value setting results in a higher number of false positives and less probability of eliminating a true positive by automated filtering; settings above -p 0.0001 are recommended). Table 1 . Discard the peptides for which mass ambiguities cannot be resolved even with the high mass accuracy data (e.g., preceding arginine, preceding isoleucine or leucine if urea was used in the sample, preceding valine and preceding GV/VG sequence).
14|
Validate the arginylated peptide spectra manually by isotopic peak checking. Manually view the precursor ion in the mass spectrum (MS spectrum) for each of these peptides in the Xcalibur Raw file using the Qual Browser program (Thermo Fisher) to see whether the theoretical isotopic peak agrees with the experimentally identified one. Spectra can be viewed by opening the Raw file with the Qual Browser and finding the corresponding scan numbers (as identified in the file produced after database searching) in the raw data. For example, if the calculated mass (M) of the identified peptide is 1,500, and the measured mass of the peptide is 1,501, check the peak in the corresponding MS spectrum in the Raw file to confirm that the measured peak is indeed the M+1 peak, (which occurs if one of the carbons in the peptide is a heavy 13 C; Fig. 3) . If the measured mass of the peptide is 1,500, then confirm that the peak in the corresponding MS spectrum is a monoisotopic peak. If this cannot be confirmed, eliminate the corresponding peptides as false positives. peptides in the Xcalibur Raw file using the Qual Browser program by manual viewing to identify the b ion series. Addition of Nterminal Arg onto peptides is expected to result in an altered pattern of fragment ions generated from the peptide's N terminus (b ion series). Arginylated peptides usually have more prominent early b ions (corresponding to the lower mass fragments generated from the N terminus) (Fig. 4) 2, 5, 18, 19 . ? TROUBLESHOOTING 16| Perform additional data validation as needed to verify the identified arginylated peptides, using one or more of the following options: (A) high-resolution MS/MS analysis; (B) comparison of the identified spectra with the spectra of synthetic peptides with the same sequence; and (C) perform additional analysis to obtain more structural information on the peptides, as outlined below. (A) High-resolution MS/MS analysis (i) Confirm arginylated peptides by high-resolution MS/MS analysis. m CRITICAL STEP If the abundance of the arginylated protein is low and high sensitivity is required, mass spectrometers with lower mass accuracy, such as LTQ, could be used for MS/MS, followed by extensive manual validation. (B) Comparison of the identified spectra with the spectra of synthetic peptides with the same sequence (i) For ambiguous and/or biologically important peptides, compare the spectrum found in the real sample with the spectrum of a synthetic peptide with the same sequence using the same instrument and the same conditions. To resolve each particular mass ambiguity, synthesize both arginylated and alternatively modified peptides and compare the real sample with both standards under the same conditions. (C) Additional analysis to obtain more structural information (i) Obtain additional structural information on the peptides by triple quadrupole MS, PQD or MS3 mass analysis to detect the b 1 ion corresponding to Arg residue fragmented off the N terminus.
? TROUBLESHOOTING Troubleshooting advice can be found in The peptide underwent another modification that produced a similar mass to arginine Discard initial hits that do not pass automated data filtering 14 Peptides identified with high mass accuracy and without obvious ambiguities do not pass isotopic peak checking
The peptide underwent another modification that produced a similar mass to arginine
Hypothetically at some stages during MS analysis peptides may undergo unanticipated modifications, such as neutral loss of hydrogen that results in a mass shift of -1. At present, we discard the peptides that do not pass the isotopic peak checking even if they fit all the other criteria, but it is possible that in the future an explanation for such mass shifts can be found and peptides with mass shift of -1 can be considered Step(s) Problem Possible reasons Solution
14
Mass spectrum contains a mixture of ions that appears too complex for one peptide
In some cases, co-eluting peptides may have very similar m/z values and appear in the same isolation window, resulting in isotopic envelopes for more than one peptide appearing together in the corresponding MS spectrum
Check whether at least one of the measured masses in the isolation window matches to the calculated mass with the correct isotopic peak with an acceptable delta mass. In this case, the peptide is considered to be a putative true hit 15 The absence of the first 5 to 6 b ions in the identifiable quantities in the mass spectrum
The peptide underwent another modification that produced a similar mass to arginine (for example, acetylation of aspartate)
b ions in the spectrum should be identified and compared with the theoretical masses for these ions. Consistently observed accuracy within 0.3 Da between the identified b ion masses and the theoretically calculated ones suggest that the peptide is truly arginylated. Absence or inaccuracy of b ion masses greater than 0.3 Da indicates a false positive that should be eliminated b ion masses are consistently borderline; some are within 0.3 Da of those theoretically predicted, whereas others differ by 0.3 Da or more
The peptide underwent another modification that produced a similar mass to arginine Whenever comparison of calculated and observed b ion masses cannot give a definitive answer, standard peptides with similar sequence should be run under the same conditions and the spectra for the standard peptides should be compared with those in the real sample
